Predictor for Histological Microvascular Invasion of Hepatocellular Carcinoma: a Lesson from 229 Consecutive Cases of Curative Liver Resection
Overview
Authors
Affiliations
Background: Microscopic vascular invasion is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. To predict microscopic portal venous invasion, the following two questions were examined retrospectively: Is it possible to detect microvascular invasion preoperatively? What are the characteristics of a group of early HCC recurrences even with no microvascular invasion?
Methods: Study 1 included 229 patients with HCC who underwent curative liver resection between 1991 and 2008; 127 had HCC without microscopic portal venous invasion, and 52 had HCC with microscopic portal venous invasion (MPVI). These two distinct groups were analyzed with regard to various clinicopathologic factors. Subsequently, we specifically investigated if HCCs <5 cm with vascular invasion (n = 32) have some characteristics that would allow detection of latent microvascular invasion. Study 2 included 127 HCC patients without MVPI; 42 had a recurrence within 2 years, and 85 patients were recurrence-free for at least 2 years. These two distinct groups were analyzed with regard to various clinicopathologic factors.
Results: HCC diameter of >5 cm, the macroscopic appearance of HCC, and high levels of preoperative des-gamma-carboxyprothrombin are significant prognostic factors in identifying microvascular invasion of HCC. The strongest predictor of early recurrence (within 2 years) was the serum alpha-fetoprotein level in patients without clear microvascular invasion.
Conclusions: Tumor size, macroscopic appearance, and high tumor marker levels are important elements in identifying the group of patients with a low HCC recurrence rate after curative liver resection.
Birgin E, Nebelung H, Abdelhadi S, Rink J, Froelich M, Hetjens S Front Oncol. 2024; 14:1360936.
PMID: 39376989 PMC: 11457731. DOI: 10.3389/fonc.2024.1360936.
Pei J, Wang L, Li H J Comput Assist Tomogr. 2024; 49(1):9-22.
PMID: 38663025 PMC: 11801467. DOI: 10.1097/RCT.0000000000001618.
The influencing factors for tumor thrombus in patients with hepatocellular carcinoma.
Ma J, Li D, Zhu X J Gastrointest Oncol. 2024; 15(1):415-424.
PMID: 38482224 PMC: 10932677. DOI: 10.21037/jgo-23-983.
Cai Y, Xie K, Adeeb Alhmoud M, Lan T, Wan H, Hu D Cancer Med. 2023; 12(17):17866-17877.
PMID: 37596739 PMC: 10523999. DOI: 10.1002/cam4.6422.
Huang J, Li L, Liu F, Tan B, Yang Y, Jiang B J Hepatocell Carcinoma. 2023; 10:573-586.
PMID: 37056420 PMC: 10086221. DOI: 10.2147/JHC.S404895.